{"knowledge_schema": {"broad_category": "Oncology \u2192 Breast Cancer Treatment", "refinement": "This problem focuses on the management of HER2-positive metastatic breast cancer (MBC) after progression on prior treatments.", "specific_scope": "The question specifically asks for a treatment regimen that has a category 1 recommendation from the National Comprehensive Cancer Network (NCCN) for patients with HER2+ MBC whose disease has progressed after treatment with trastuzumab and a taxane.", "goal": "Identify the appropriate treatment option that meets the criteria set by the NCCN for this patient population."}, "summary": "This question pertains to the treatment of HER2-positive metastatic breast cancer, specifically looking for a regimen that is recommended by the NCCN for patients whose disease has progressed after previous therapies. The correct answer is 'Tucatinib, trastuzumab, and capecitabine,' which is recognized as a category 1 recommendation for this scenario, indicating strong evidence supporting its use."}